Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.
Sood
Anil K
AK
Department of Gynecologic Oncology, University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030, USA. asood@mdanderson.org
Lush
Richard
R
Geisler
John P
JP
Shahin
Mark S
MS
Sanders
Linda
L
Sullivan
Dan
D
Buller
Richard E
RE
Sorosky
Joel I
JI
D000284:Administration, Oral; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000097:blood / Q000627:therapeutic use*; D019540:Area Under Curve; D002277:Carcinoma / Q000097:blood / Q000188:drug therapy; D002851:Chromatography, High Pressure Liquid; D004247:DNA / Q000378:metabolism; D018450:Disease Progression; D005047:Etoposide / Q000008:administration & dosage* / Q000097:blood; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy*; D010534:Peritoneal Neoplasms / Q000097:blood / Q000188:drug therapy*; D012008:Recurrence; D013997:Time Factors; D019772:Topotecan / Q000008:administration & dosage* / Q000097:blood; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide; D019772:Topotecan; D004247:DNA